Skip to main content

David Charles Montefiori, PhD

Professor of Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Publications

Gray, Glenda E., Ying Huang, Nicole Grunenberg, Fatima Laher, Surita Roux, Erica Andersen-Nissen, Stephen C. De Rosa, et al. “Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.” Sci Transl Med 11, no. 510 (September 18, 2019). https://doi.org/10.1126/scitranslmed.aax1880.

Full Text

Wee, Edmund G., Nathifa A. Moyo, Kevin O. Saunders, Celia LaBranche, Filippo Donati, Silvia Capucci, Robert Parks, et al. “Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.” Mol Ther Methods Clin Dev 14 (September 13, 2019): 148–60. https://doi.org/10.1016/j.omtm.2019.06.003.

Full Text

LaBranche, Celia C., Rory Henderson, Allen Hsu, Shay Behrens, Xuejun Chen, Tongqing Zhou, Kevin Wiehe, et al. “Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.” Plos Pathog 15, no. 9 (September 2019): e1008026. https://doi.org/10.1371/journal.ppat.1008026.

Full Text

Bricault, Christine A., Karina Yusim, Michael S. Seaman, Hyejin Yoon, James Theiler, Elena E. Giorgi, Kshitij Wagh, et al. “HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.” Cell Host Microbe 26, no. 2 (August 14, 2019): 296. https://doi.org/10.1016/j.chom.2019.07.016.

Full Text

Jones, Dorothy I., Justin J. Pollara, Brandi T. Johnson-Weaver, Celia C. LaBranche, David C. Montefiori, David J. Pickup, Sallie R. Permar, et al. “Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.” J Virol 93, no. 14 (July 15, 2019). https://doi.org/10.1128/JVI.00475-19.

Full Text

Han, Qifeng, Julia A. Jones, Nathan I. Nicely, Rachel K. Reed, Xiaoying Shen, Katayoun Mansouri, Mark Louder, et al. “Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations.” Nat Commun 10, no. 1 (July 1, 2019): 2898. https://doi.org/10.1038/s41467-019-10899-2.

Full Text

Escolano, Amelia, Harry B. Gristick, Morgan E. Abernathy, Julia Merkenschlager, Rajeev Gautam, Thiago Y. Oliveira, Joy Pai, et al. “Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.” Nature 570, no. 7762 (June 2019): 468–73. https://doi.org/10.1038/s41586-019-1250-z.

Full Text

Sliepen, Kwinten, Byung Woo Han, Ilja Bontjer, Petra Mooij, Fernando Garces, Anna-Janina Behrens, Kimmo Rantalainen, et al. “Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence.” Nat Commun 10, no. 1 (May 29, 2019): 2355. https://doi.org/10.1038/s41467-019-10262-5.

Full Text

Wang, Qian, Lihong Liu, Wuze Ren, Agegnehu Gettie, Hua Wang, Qingtai Liang, Xuanling Shi, David C. Montefiori, Tongqing Zhou, and Linqi Zhang. “A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation.” Cell Rep 27, no. 9 (May 28, 2019): 2593-2607.e5. https://doi.org/10.1016/j.celrep.2019.04.108.

Full Text

Pollara, Justin, Dorothy I. Jones, Tori Huffman, R Whitney Edwards, Maria Dennis, Shuk Hang Li, Shalini Jha, et al. “Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models.” J Virol 93, no. 10 (May 15, 2019). https://doi.org/10.1128/JVI.02119-18.

Full Text

Pages